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The emergent evaluation and management of patients with possible acute heart failure syndromes (AHFS) remains a significant challenge. Unlike major advances in the assessment and treatment of patients with acute coronary syndromes, the diagnostic tools and therapeutic options for patients presenting with AHFS have changed little for decades (1) , and the complexity of AHFS has led to a practice of risk aversion and extremely high hospitalization rates (2) (3) (4) (5) . These difficulties, as well as the increasing prevalence of heart failure, have placed an enormous burden on health care resources worldwide (2).
The cohort of AHFS patients is diverse. Although they might be commonly defined as patients with a gradual or rapid change in chronic heart failure signs and symptoms resulting in a need for urgent or unscheduled therapy (4, 6, 7) , the development, presentation, and response to treatment is dependent on each individual's pathophysiology and comorbidities. Researchers have studied a wide range of patient populations with different eligibility criteria and medical histories and using divergent outcome measures. To better interpret available research in the light of this study-related heterogeneity and to improve the level of evidence supporting the acute evaluation and management of the AHFS patient, it is critical to present a thorough description of the patient population evaluated. Methods of patient selection, demographics and medical history of eligible patients, intervention or evaluation protocols, outcome measures, and time intervals for measurements must be consistently reported. Based on existing recommendations and expert consensus, these guidelines aim to provide investigators a framework for reporting studies of patients with possible AHFS. By providing these standardized reporting criteria, we hope to improve the interpretability of research in this challenging patient cohort and thus to improve patient care through better application of evidence-based medicine.
Development of Criteria
A working group of the Emergency Management and Research Group in Acute Heart Failure met in May 2007 to begin developing the reporting guidelines. Eight areas of importance were identified and assigned to working group members to develop initial recommendations based on existing guidelines:
1 
Structure and Suggestions for Use of This Document
These guidelines emphasize the minimum information that should be reported and additional information that would be of benefit to report when presenting studies of the evaluation and management of AHFS. The structure is similar to recently introduced reporting guidelines for possible acute coronary syndromes (8) . Where available, we have used the definition of data elements as provided by the American College of Cardiology, American Heart Association, European Society of Cardiology, Heart Failure Society of America, Society of Chest Pain Centers, or World Heart Federation (9 -18). Where definitions do not exist or are insufficient to clarify ambiguity in reporting, new definitions have been provided.
Throughout the document, bolded items are identified as core components (Table 1) , and these should be reported in all studies of the evaluation and management of AHFS. Supplemental items are not bolded but should be reported whenever possible. Core components represent the minimal amount of information necessary to compare and contrast studies and can be used by investigators to guide data collection and presentation of results. As well as facilitating the design of studies, peer reviewers evaluating manuscripts for publication may use these criteria to determine whether sufficient information is reported to allow readers to place the study in appropriate context and compare results with those of other publications. Clinicians may find it helpful to use the core criteria to determine whether reported populations are similar to the patients they treat and thus facilitate an evidence-based medicine approach to the acute evaluation and management of AHFS. Reporting AHFS studies in accordance with the guidelines will facilitate systematic review and meta-analysis, maximizing the impact of research on clinical practice.
Screening and Recruitment
Patients with AHFS are a heterogeneous population. The performance of diagnostic and prognostic interventions is dependent on the severity, prevalence, and pathophysiology of the disease in the study population, as well as comorbid conditions or alternative diagnoses. The methods of screening and recruiting subjects and study inclusion and exclusion criteria are key factors affecting these parameters and thus should be reported. 
Demographics
A description of the patients studied is important to understand the relevance of the study to specific populations to allow comparisons of different patient populations and for risk adjustments. 
Test Reporting
The tests used to evaluate patients with AHFS in the acute setting typically include the electrocardiogram (ECG), chest radiographs, and laboratory assays. Each of these should be reported with sufficient detail to enable accurate interpretation of the results. The lab result section (5.3) is meant to be an overview for both diagnostic and therapeutic studies. More detailed recommendations about biomarker reporting are available elsewhere (27-30). Marker performance relative to defined outcomes. This is a core requirement if the primary objective of the investigation is assessment of marker performance; otherwise, it is a supplemental criterion.
5.3.5. Relevant confounders for the assays being used. This is a core requirement if the primary objective of the investigation is assessment of marker performance; otherwise, it is a supplemental criterion.
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